Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sumatriptan

FDA-approved product (spray, nasal), marketed as Imitrex, Sumatriptan, Tosymra and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sumatriptan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective serotonin (5ht1) agonists
FDA pharmacologic class
Serotonin-1b and Serotonin-1d Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sumatriptan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sumatriptan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

    NCT02856802 · start 2016-07-11

    Registered record
    Registry ID
    NCT02856802
    Conditions
    Migraine Headaches
    Interventions
    Sumatriptan 10 mg Nasal Spray; Sumatriptan Placebo Nasal Spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07-11
    Completion
    2017-02-10
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headaches
    InterventionSumatriptan 10 mg Nasal Spray; Sumatriptan Placebo Nasal Spray
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan

    NCT02741310 · start 2016-02-22

    Registered record
    Registry ID
    NCT02741310
    Conditions
    Healthy Subjects
    Interventions
    Placebo; Sumatriptan; Erenumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-22
    Completion
    2016-08-11
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionPlacebo; Sumatriptan; Erenumab
    PhasePhase 1
    Registry statusCompleted

  • Migraine Treatment in ED

    NCT02643719 · start 2015-12

    Registered record
    Registry ID
    NCT02643719
    Conditions
    Migraine
    Interventions
    Relaxation Therapy; Topiramate; Standard of Care; Abortive Medication (Naproxen and Sumatriptan)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2015-12
    Completion
    2017-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionRelaxation Therapy; Topiramate; Standard of Care; Abortive Medication (Naproxen and Sumatriptan)
    PhaseNot applicable
    Registry statusWithdrawn

  • Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

    NCT02176655 · start 2014-07

    Registered record
    Registry ID
    NCT02176655
    Conditions
    Delayed Alcohol Induced Headache
    Interventions
    VVD-101; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Alcohol Induced Headache
    InterventionVVD-101; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

    NCT02684409 · start 2013-08

    Registered record
    Registry ID
    NCT02684409
    Conditions
    Acute Migraine
    Interventions
    PROT-CL-NP101-015.01
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-11
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Migraine
    InterventionPROT-CL-NP101-015.01
    PhasePhase 1
    Registry statusCompleted

  • Safety Tolerability and Pharmacokinetics of ALD403

    NCT01579383 · start 2012-04

    Registered record
    Registry ID
    NCT01579383
    Conditions
    Migraine Disorders
    Interventions
    ALD403; ALD403; Sumatriptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2013-04
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionALD403; ALD403; Sumatriptan
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects

    NCT01507610 · start 2012-01

    Registered record
    Registry ID
    NCT01507610
    Conditions
    Migraine
    Interventions
    Sumatriptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionSumatriptan
    PhasePhase 1
    Registry statusCompleted

  • CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

    NCT01329562 · start 2011-05

    Registered record
    Registry ID
    NCT01329562
    Conditions
    Menstrual Migraine
    Interventions
    Treximet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-06
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenstrual Migraine
    InterventionTreximet; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

    NCT01462812 · start 2011-01

    Registered record
    Registry ID
    NCT01462812
    Conditions
    Migraine Headache
    Interventions
    Sumatriptan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-06
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache
    InterventionSumatriptan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine

    NCT01300546 · start 2010-12

    Registered record
    Registry ID
    NCT01300546
    Conditions
    Migraine
    Interventions
    Sumatriptan/Naproxen Sodium; Naproxen Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionSumatriptan/Naproxen Sodium; Naproxen Sodium
    PhasePhase 4
    Registry statusCompleted

  • Treximet Early Intervention Adolescent Migraine

    NCT01016678 · start 2010-03

    Registered record
    Registry ID
    NCT01016678
    Conditions
    Migraine
    Interventions
    Treximet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2014-07
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionTreximet; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy

    NCT01381497 · start 2010-03

    Registered record
    Registry ID
    NCT01381497
    Conditions
    Migraine Disorders
    Interventions
    Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Triptan monotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders
    InterventionCombination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Triptan monotherapy
    PhaseNot recorded
    Registry statusCompleted

  • Trial of Comprehensive Migraine Intervention

    NCT01071317 · start 2010-02

    Registered record
    Registry ID
    NCT01071317
    Conditions
    Migraine
    Interventions
    Naproxen; Sumatriptan; Migraine education; Reenforcement of diagnosis; Typical care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2012-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNaproxen; Sumatriptan; Migraine education; Reenforcement of diagnosis +1 more
    PhasePhase 4
    Registry statusCompleted

  • Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex

    NCT01450995 · start 2009-12

    Registered record
    Registry ID
    NCT01450995
    Conditions
    Migraine
    Interventions
    Treximet; Imitrex and two Aleve
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionTreximet; Imitrex and two Aleve
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

    NCT01916395 · start 2009-12

    Registered record
    Registry ID
    NCT01916395
    Conditions
    Migraine
    Interventions
    sumatriptan and Treximet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-12
    Completion
    2011-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    Interventionsumatriptan and Treximet
    PhaseNot recorded
    Registry statusCompleted